KAT2B and breast cancer: Notably, genetic and pharmacological inactivation of KAT2B results in impaired EMT and loss of stemness properties, similar to NELF-E ablation, thereby establishing the functional importance of the NELF-E-KAT2B regulatory axis in breast cancer carcinogenesis.